Cabio Biotech (Wuhan) Co., Ltd. (SHA:688089)

China · Delayed Price · Currency is CNY

7.42

-0.02 (-0.27%)

Aug 4, 2026, 3:00 PM CST

-72.80% (1Y)

Market Cap	1.22B -73.4%
Revenue (ttm)	418.18M -29.7%
Net Income	55.16M -61.9%
EPS	0.33 -62.2%
Shares Out	164.51M
PE Ratio	22.51
Forward PE	n/a
Dividend	0.20 (2.71%)
Ex-Dividend Date	Jul 10, 2025

Volume	4,867,995
Open	7.38
Previous Close	7.44
Day's Range	7.34 - 7.65
52-Week Range	6.91 - 31.13
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 22, 2026

About Cabio Biotech (Wuhan)

Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production, and sale of functional ingredients and bio-based products in China and internationally. The company offers polyunsaturated fatty acids, including arachidonic acid (ARA) and docosahexaenoic acid (DHA); terpenoids, such as beta (β)-carotene and astaxanthin; and carbohydrates, such as N-acetylneuraminic acid and human milk oligosaccharides. Its products are used in human nutrition, including early life nutrition and dietary supplements; animal nutrition, such as econ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1999

Employees 595

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688089

Full Company Profile

Financial Performance

In 2025, Cabio Biotech (Wuhan)'s revenue was 563.14 million, an increase of 1.36% compared to the previous year's 555.59 million. Earnings were 143.72 million, an increase of 15.71%.

Financial Statements